Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 19/20 | 0.47 |
| ▸ | TLR8 | Q9NR97 | 9/20 | 0.45 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1490411 | 0.96 | TLR7 (0.48) | TLR7TLR8NUDT1 | |
| SCHEMBL3867540 | 0.89 | TLR7 (0.51) | TLR7TLR8NUDT1 | |
| SCHEMBL1616868 | 0.87 | TLR8 (0.61) | TLR7TLR8NUDT1 | |
| SCHEMBL2744526 | 0.86 | TLR7 (0.50) | TLR7TLR8 | |
| SCHEMBL3872419 | 0.85 | TLR7 (0.52) | TLR7TLR8NUDT1 | |
| SCHEMBL14592739 | 0.82 | TLR7 (0.63) | TLR7TLR8 | |
| SCHEMBL1490891 | 0.82 | TLR8 (0.59) | TLR7TLR8NUDT1 | |
| SCHEMBL1490683 | 0.81 | TLR7 (0.61) | TLR7TLR8NUDT1 | |
| SCHEMBL4080325 | 0.81 | TLR8 (0.54) | TLR7TLR8NUDT1 | |
| SCHEMBL4594183 | 0.80 | TLR8 (0.46) | TLR7TLR8NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897767-B2 | Oxime substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-03-01 | — | — | US | disclosed |
| US-7897767-B2 | Oxime substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-03-01 | — | — | US | disclosed |
| US-7897767-B2 | Oxime substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-03-01 | — | — | US | disclosed |
| US-20090042925-A1 | OXIME SUBSTITUTED IMIDAZOQUINOLINES | COLEY PHARMACEUTICAL GROUP, INC. | 2009-02-12 | — | — | US | disclosed |
| US-20090042925-A1 | OXIME SUBSTITUTED IMIDAZOQUINOLINES | COLEY PHARMACEUTICAL GROUP, INC. | 2009-02-12 | — | — | US | disclosed |
| US-20090042925-A1 | OXIME SUBSTITUTED IMIDAZOQUINOLINES | COLEY PHARMACEUTICAL GROUP, INC. | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042925-A1 | OXIME SUBSTITUTED IMIDAZOQUINOLINES | IFNG, IL2, IRF3 | TLR7 33/4885TLR8 88/4885NUDT1 997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.